Which has stronger valuation & earnings, EXEL or TLX?

Exelixis has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.24 $782.57M $3.18 18.37 Telix Pharmaceuticals $803.79M 4.54 -$7.12M N/A N/A

Does the media prefer EXEL or TLX?

In the previous week, Telix Pharmaceuticals had 9 more articles in the media than Exelixis. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 4 mentions for Exelixis. Exelixis' average media sentiment score of 0.85 beat Telix Pharmaceuticals' score of 0.43 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, ASND or TLX?

Telix Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 17.41 -$258M $12.89 17.63 Telix Pharmaceuticals $803.79M 4.54 -$7.12M N/A N/A

Does the media refer more to ASND or TLX?

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 9 mentions for Ascendis Pharma A/S. Telix Pharmaceuticals' average media sentiment score of 0.43 beat Ascendis Pharma A/S's score of 0.18 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, SMMT or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Telix Pharmaceuticals $803.79M 4.54 -$7.12M N/A N/A

Is SMMT or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Telix Pharmaceuticals N/A N/A N/A

Does the media favor SMMT or TLX?

In the previous week, Summit Therapeutics had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 17 mentions for Summit Therapeutics and 13 mentions for Telix Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.59 beat Telix Pharmaceuticals' score of 0.43 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Telix Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, BBIO or TLX?

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 25.59 -$724.93M -$3.57 N/A Telix Pharmaceuticals $803.79M 4.54 -$7.12M N/A N/A

Is BBIO or TLX more profitable?

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma -97.03% N/A -61.19% Telix Pharmaceuticals N/A N/A N/A

Does the media favor BBIO or TLX?

In the previous week, Telix Pharmaceuticals had 7 more articles in the media than BridgeBio Pharma. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 6 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.72 beat Telix Pharmaceuticals' score of 0.43 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, HALO or TLX?

Halozyme Therapeutics has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Halozyme Therapeutics $1.66B 7.40 $316.89M $3.35 32.39 Telix Pharmaceuticals $803.79M 4.54 -$7.12M N/A N/A

Does the media prefer HALO or TLX?

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 8 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.53 beat Telix Pharmaceuticals' score of 0.43 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Telix Pharmaceuticals (TLX) Competitors

$10.76 -0.22 (-1.96%)

As of 12:04 PM Eastern

Compare

TLX vs. EXEL, ASND, SMMT, BBIO, and HALO

Should you buy Telix Pharmaceuticals stock or one of its competitors? Telix Pharmaceuticals's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Telix Pharmaceuticals compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Exelixis has a net margin of 35.33% compared to Telix Pharmaceuticals' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Telix Pharmaceuticals	N/A	N/A	N/A

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Telix Pharmaceuticals had 9 more articles in the media than Exelixis. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 4 mentions for Exelixis. Exelixis' average media sentiment score of 0.85 beat Telix Pharmaceuticals' score of 0.43 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.24	$782.57M	$3.18	18.37
Telix Pharmaceuticals	$803.79M	4.54	-$7.12M	N/A	N/A

Exelixis currently has a consensus price target of $50.29, indicating a potential downside of 13.94%. Telix Pharmaceuticals has a consensus price target of $20.50, indicating a potential upside of 90.96%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Exelixis has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

Summary

Exelixis beats Telix Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Ascendis Pharma A/S has a net margin of 70.99% compared to Telix Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 9 mentions for Ascendis Pharma A/S. Telix Pharmaceuticals' average media sentiment score of 0.43 beat Ascendis Pharma A/S's score of 0.18 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market.

Ascendis Pharma A/S currently has a consensus price target of $310.75, indicating a potential upside of 36.71%. Telix Pharmaceuticals has a consensus price target of $20.50, indicating a potential upside of 90.96%. Given Telix Pharmaceuticals' higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Telix Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.41	-$258M	$12.89	17.63
Telix Pharmaceuticals	$803.79M	4.54	-$7.12M	N/A	N/A

Summary

Ascendis Pharma A/S beats Telix Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Telix Pharmaceuticals has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Telix Pharmaceuticals	$803.79M	4.54	-$7.12M	N/A	N/A

Summit Therapeutics presently has a consensus price target of $28.61, suggesting a potential upside of 65.10%. Telix Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 90.96%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summit Therapeutics has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

In the previous week, Summit Therapeutics had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 17 mentions for Summit Therapeutics and 13 mentions for Telix Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.59 beat Telix Pharmaceuticals' score of 0.43 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Telix Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals' return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Telix Pharmaceuticals	N/A	N/A	N/A

Summary

Telix Pharmaceuticals beats Summit Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Telix Pharmaceuticals	N/A	N/A	N/A

99.9% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.59	-$724.93M	-$3.57	N/A
Telix Pharmaceuticals	$803.79M	4.54	-$7.12M	N/A	N/A

BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market.

BridgeBio Pharma currently has a consensus price target of $102.61, indicating a potential upside of 56.14%. Telix Pharmaceuticals has a consensus price target of $20.50, indicating a potential upside of 90.96%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Telix Pharmaceuticals had 7 more articles in the media than BridgeBio Pharma. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 6 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.72 beat Telix Pharmaceuticals' score of 0.43 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Telix Pharmaceuticals beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

Halozyme Therapeutics currently has a consensus price target of $91.20, suggesting a potential downside of 15.95%. Telix Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 90.96%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Halozyme Therapeutics has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.40	$316.89M	$3.35	32.39
Telix Pharmaceuticals	$803.79M	4.54	-$7.12M	N/A	N/A

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 8 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.53 beat Telix Pharmaceuticals' score of 0.43 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Halozyme Therapeutics has a net margin of 24.86% compared to Telix Pharmaceuticals' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Telix Pharmaceuticals	N/A	N/A	N/A

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Telix Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.65B	$3.91B	$7.14B	$13.03B
Dividend Yield	N/A	3.63%	2.52%	14.40%
P/E Ratio	N/A	13.63	273.40	25.72
Price / Sales	4.54	1,296.79	656.38	105.87
Price / Cash	268.95	120.99	79.75	52.21
Price / Book	8.73	15.39	10.42	6.25
Net Income	-$7.12M	-$22.67M	$3.49B	$360.73M
7 Day Performance	-5.08%	-2.64%	-1.99%	-1.92%
1 Month Performance	-1.06%	-8.58%	-5.15%	-3.43%
1 Year Performance	5.56%	24.00%	10.38%	2.46%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	4.605 of 5 stars	$10.74 -2.1%	$20.50 +91.0%	+14.6%	$3.65B	$803.79M	N/A	1,152
EXEL Exelixis	3.141 of 5 stars	$57.88 -0.8%	$50.29 -13.1%	+41.4%	$14.35B	$2.32B	18.21	1,077
ASND Ascendis Pharma A/S	4.8137 of 5 stars	$225.21 -2.1%	$310.75 +38.0%	+14.6%	$14.07B	$814.57M	17.50	1,189
SMMT Summit Therapeutics	2.8676 of 5 stars	$16.49 +6.5%	$28.22 +71.2%	-18.2%	$13.11B	N/A	N/A	265	Analyst Forecast High Trading Volume
BBIO BridgeBio Pharma	3.2709 of 5 stars	$66.63 +0.0%	$102.61 +54.0%	+26.7%	$13.04B	$502.08M	N/A	839

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Telix Pharmaceuticals compare to Exelixis?

Summary

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Telix Pharmaceuticals compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Telix Pharmaceuticals compare to Exelixis?

Is EXEL or TLX more profitable?

Do insiders and institutionals have more ownership in EXEL or TLX?

Does the media prefer EXEL or TLX?

Which has stronger valuation & earnings, EXEL or TLX?

Do analysts prefer EXEL or TLX?

Which has more volatility & risk, EXEL or TLX?

Summary

How does Telix Pharmaceuticals compare to Ascendis Pharma A/S?

Is ASND or TLX more profitable?

Does the media refer more to ASND or TLX?

Which has more risk and volatility, ASND or TLX?

Do analysts recommend ASND or TLX?

Which has higher valuation & earnings, ASND or TLX?

Summary

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Which has better valuation & earnings, SMMT or TLX?

Do analysts prefer SMMT or TLX?

Do institutionals and insiders have more ownership in SMMT or TLX?

Which has more volatility and risk, SMMT or TLX?

Does the media favor SMMT or TLX?

Is SMMT or TLX more profitable?

Summary

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Is BBIO or TLX more profitable?

Do insiders & institutionals believe in BBIO or TLX?

Which has higher valuation & earnings, BBIO or TLX?

Which has more risk & volatility, BBIO or TLX?

Do analysts recommend BBIO or TLX?

Does the media favor BBIO or TLX?

Summary

How does Telix Pharmaceuticals compare to Halozyme Therapeutics?

Which has more volatility & risk, HALO or TLX?

Do analysts prefer HALO or TLX?

Which has better earnings and valuation, HALO or TLX?

Does the media prefer HALO or TLX?

Is HALO or TLX more profitable?

Do insiders and institutionals have more ownership in HALO or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools